+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Stevens-Johnson Syndrome and toxic epidermal necrolysis: a multi-aspect comparative 7-year study from the People's Republic of China



Stevens-Johnson Syndrome and toxic epidermal necrolysis: a multi-aspect comparative 7-year study from the People's Republic of China



Drug Design, Development and Therapy 8: 2539-2547



Stevens-Johnson Syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare but severe cutaneous drug reactions. They are differentiated based on the fraction of the body surface area affected. Optimal therapy for SJS and TEN is a controversial issue. We compared the treatments given to and the clinical outcomes of 39 cases of SJS and 48 cases of TEN seen at a single institution between January 2007 and December 2013 for better understanding of the clinical characteristics and development of the two conditions. Demographic data, clinical characteristics, treatments given, and therapeutic responses observed were retrospectively collected. The incidence rates of hypoproteinemia and secondary infections are significantly higher in TEN than in SJS (P=0.001 and P=0.002, respectively). The corticosteroid dose did not influence the time from the initiation of therapy to control of the lesions in SJS, but increasing the dosage of corticosteroids progressively decreased the time from the initiation of therapy to control of the lesions in TEN. With increases in the utilization ratio of intravenous immunoglobulin (IVIG), the length of the hospital stay became shorter, whereas the time from the initiation of therapy to control of the lesions remained the same in SJS. However, for TEN, both the length of the hospital stay and the time from the initiation of therapy to control of the lesions became shorter with increases in the utilization ratio of IVIG. SJS and TEN are two variants of the same spectrum, and they differ from each other not only in the severity of epidermal detachment but also in other clinical parameters and their distinct clinical courses. Thus, differential treatment of both conditions may have benefits for their prognosis.

(PDF emailed within 0-6 h: $19.90)

Accession: 058905137

Download citation: RISBibTeXText

PMID: 25548516

DOI: 10.2147/DDDT.S71736


Related references

Combination therapy of intravenous immunoglobulin and corticosteroid in the treatment of toxic epidermal necrolysis and Stevens-Johnson syndrome: a retrospective comparative study in China. International Journal of Dermatology 48(10): 1122-1128, 2009

Stevens-Johnson syndrome and toxic epidermal necrolysis: a 15-year retrospective study. Acta Medica Portuguesa 24(1): 59-70, 2011

A cross-sectional comparative study on chronic ocular manifestations of Stevens-Johnson syndrome and toxic epidermal necrolysis in Chinese eyes: a 15-year case series. International Ophthalmology 38(3): 1155-1160, 2017

Characteristics of toxic epidermal necrolysis and Stevens-Johnson syndrome: a 5-year retrospective study. Journal of the Medical Association of Thailand 96(4): 399-406, 2013

Toxic epidermal necrolysis and Stevens-Johnson syndrome in South Africa: a 3-year prospective study. Qjm 105(9): 839-846, 2013

The Epidemiology of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in China. Journal of Immunology Research 2018: 4320195, 2018

Stevens-Johnson syndrome and toxic epidermal necrolysis; therapy policy in these life-threatening illnesses. Netherlands Work Group Toxic Epidermal Necrolysis. Nederlands Tijdschrift Voor Geneeskunde 140(30): 1538-1543, 1996

Investigation of Monnose-Binding Lectin gene Polymorphism in Patients with Erythema Multiforme, Stevens-Johnson Syndrome and Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis Overlap Syndrome. Balkan Medical Journal 29(3): 310-313, 2012

Use of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis and Stevens-Johnson/toxic epidermal necrolysis overlap syndrome. Review of 15 cases. Revista Medica de Chile 137(3): 383-389, 2010

A clinicotherapeutic analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis with an emphasis on the predictive value and accuracy of SCORe of Toxic Epidermal Necrolysis. International Journal of Dermatology 54(1): E18-E26, 2015

Toll-like receptor 9 polymorphism in patients with erythema multiforme, Stevens Johnson syndrome and Stevens Johnson syndrome/toxic epidermal necrolysis overlap syndrome. Bratislavske Lekarske Listy 112(5): 260-263, 2011

Comparison of the acute ocular manifestations of Stevens-Johnson syndrome and toxic epidermal necrolysis in Chinese eyes: a 15-year retrospective study. Bmc Ophthalmology 17(1): 65, 2017

Clinical Features and Treatment Outcomes among Children with Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A 20-Year Study in a Tertiary Referral Hospital. Dermatology Research and Practice 2018: 3061084, 2018

Stevens-Johnson syndrome and toxic epidermal necrolysis: a 20-year single-center experience. International Journal of Dermatology 54(8): 978-984, 2016

Erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis: a comparative review. Veterinary Dermatology 25(5): 406-E64, 2015